<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01024959</url>
  </required_header>
  <id_info>
    <org_study_id>2009PCA301</org_study_id>
    <nct_id>NCT01024959</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Previous Negative Biopsy Result</brief_title>
  <acronym>PCA3</acronym>
  <official_title>Clinical Evaluation of the PROGENSA(R) PCA3 Assay in Men With a Previous Negative Biopsy Result</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gen-Probe, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gen-Probe, Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this multi-center clinical study is to determine the association of the PCA3
      Score with prostate biopsy outcome and validate the assay's performance characteristics in
      men with previous negative prostate biopsies. An elevated PCA3 Score is thought to be
      associated with an increased likelihood of positive biopsy. The results of this study are
      intended to be used for regulatory filings for use as an in vitro diagnostic test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PCA3 is a gene that is highly over-expressed in more than 90% of prostate cancers, and that
      can be quantified in urine specimens following a digital rectal examination. Studies have
      shown that because PCA3 is highly specific for prostate cancer, it predicts the results of
      repeat biopsies more accurately than traditional prostate-specific antigen (PSA) testing.
      Gen-Probe's PROGENSA(R) PCA3 assay is the first urine-based molecular diagnostic assay for
      prostate cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Association of PCA3 Score With Prostate Biopsy Outcome (PCA3 Score Using Cutoff of 25.)</measure>
    <time_frame>At the time of biopsy</time_frame>
    <description>The likelihood of positive biopsy was determined by the PCA3 Score expressed as a binary categorical variable: PCA3 Score &gt;=25 was positive, PCA3 Score &lt;25 was negative</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">507</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>PCA3 Assay</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PCA3 Assay</intervention_name>
    <description>Post-Digital Rectal Exam (DRE) urine collected prior to prostate biopsy</description>
    <arm_group_label>PCA3 Assay</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men 40+ years of age who have had at least 1 previous negative prostate biopsy, who
             have never had a positive prostate biopsy, and who have been recommended for a repeat
             biopsy by their clinician.

          -  The subject must be able to comprehend and sign an approved informed consent form and
             other applicable study enrollment documents

        Exclusion Criteria:

          -  Use of medications or hormones that are known to affect serum PSA levels within 3 - 6
             months of study enrollment

          -  Clinical symptoms of urinary tract infection (including prostatitis) at the time of
             enrollment

          -  History of prostate cancer

          -  History of invasive treatments for benign prostatic hypertrophy (BPH) or lower urinary
             tract symptoms within 6 months of study enrollment

          -  Medical history or concurrent illness that the investigator considers sufficiently
             serious to interfere with the conduct, completion, or results of this trial, or
             constitutes an unacceptable risk to the subject

          -  Participation in pharmaceutical or treatment related clinical study within 6 months of
             study enrollment. Exception: Trials for non-prostate conditions may be acceptable,
             with approval by the investigator and Sponsor
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Reid, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gen-Probe, Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HealthCare Partners Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Clinical Trials</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialists in Urology</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Urology Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Urology, PSC</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology Specialists, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriState Urologic Services PSC Inc. dba The Urology Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Urology Research, LLC</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Urology</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2009</study_first_submitted>
  <study_first_submitted_qc>December 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2009</study_first_posted>
  <results_first_submitted>October 8, 2012</results_first_submitted>
  <results_first_submitted_qc>October 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 7, 2012</results_first_posted>
  <last_update_submitted>November 6, 2012</last_update_submitted>
  <last_update_submitted_qc>November 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Prostate Biopsy</keyword>
  <keyword>PCA3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>507 male subjects were recruited from 14 clinical sites in the United States including academic institutions, community-based urology clinics and group health organizations.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Prostate Cancer Gene 3 (PCA3) Assay</title>
          <description>PCA3 Assay : Post-Digital Rectal Exam (DRE) urine collected prior to prostate biopsy. N=495 represents the total number of subjects eligible for the study. 507 subjects were enrolled, 12 were determined to be ineligible.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="507"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="466"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>ineligible</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>results not evaluable</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>missing results required for analysis</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PCA3 Assay</title>
          <description>PCA3 Assay : Post-DRE urine collected prior to prostate biopsy. N=495 represents the total number of subjects eligible for the study. 507 subjects were enrolled, 12 were determined to be ineligible.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="495"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Association of PCA3 Score With Prostate Biopsy Outcome (PCA3 Score Using Cutoff of 25.)</title>
        <description>The likelihood of positive biopsy was determined by the PCA3 Score expressed as a binary categorical variable: PCA3 Score &gt;=25 was positive, PCA3 Score &lt;25 was negative</description>
        <time_frame>At the time of biopsy</time_frame>
        <population>A total of n=466 subjects have valid and reportable PCA3 Scores and disease status (determined by biopsy result), and who were 50 years of age or older.</population>
        <group_list>
          <group group_id="O1">
            <title>PCA3 Assay</title>
            <description>PCA3 Assay : Post-DRE urine collected prior to prostate biopsy</description>
          </group>
          <group group_id="O2">
            <title>Subjects With Positive Biopsy Result</title>
            <description>Presence of prostate cancer defined by one or more positive biopsy cores</description>
          </group>
          <group group_id="O3">
            <title>Subjects With Negative Biopsy Result</title>
            <description>Absence of prostate cancer defined by no positive biopsy cores (note: presence of high grade PIN and/or atypia are classified as negative biopsy results)</description>
          </group>
        </group_list>
        <measure>
          <title>Association of PCA3 Score With Prostate Biopsy Outcome (PCA3 Score Using Cutoff of 25.)</title>
          <description>The likelihood of positive biopsy was determined by the PCA3 Score expressed as a binary categorical variable: PCA3 Score &gt;=25 was positive, PCA3 Score &lt;25 was negative</description>
          <population>A total of n=466 subjects have valid and reportable PCA3 Scores and disease status (determined by biopsy result), and who were 50 years of age or older.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All PCA3 Scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="466"/>
                    <measurement group_id="O2" value="102"/>
                    <measurement group_id="O3" value="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCA3 Score &gt;=25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCA3 Score &lt;25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Our definition of at risk population is any unique subject who gave a post-digital rectal exam (DRE) urine sample, regardless of eligibility(n=498 of n=507 participants who started the study). n=106 of these subjects had a positive biopsy; n=389 had negative biopsy; n=3 had no biopsy.</desc>
      <group_list>
        <group group_id="E1">
          <title>PCA3 Assay</title>
          <description>PCA3 Assay : Post-DRE urine collected prior to prostate biopsy</description>
        </group>
        <group group_id="E2">
          <title>Subjects With Positive Biopsy Result</title>
          <description>Presence of prostate cancer defined by one or more positive biopsy cores</description>
        </group>
        <group group_id="E3">
          <title>Subjects With Negative Biopsy Result</title>
          <description>Absence of prostate cancer defined by no positive biopsy cores (note: presence of high grade PIN and/or atypia are classified as negative biopsy results)</description>
        </group>
        <group group_id="E4">
          <title>Subjects With no Biopsy Performed</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="498"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Reid, Director of Clinical Affairs</name_or_title>
      <organization>Gen-Probe, Incorporated</organization>
      <phone>858-731-5985</phone>
      <email>jennifer.reid@hologic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

